Wegovy News & Analysis
8 articles
Market Mood

FDA Issues New Safety Warning on GLP-1 Drugs Like Ozempic and Wegovy
The U.S. Food and Drug Administration (FDA) has issued a new safety warning for GLP-1 drugs, which include popular medications such as Ozempic and Wegovy. These drugs, used primarily for diabetes and weight management, have been linked to serious complications including eye-related issues and stroke. The warning highlights potential risks that patients and healthcare providers should be aware of. Multiple outlets, including The Washington Post, Fast Company, and MedPage Today, have reported on the FDA's advisory. Ophthalmologists and experts from Johns Hopkins have also provided guidance on the risks associated with these drugs, emphasizing caution given new findings related to eye stroke and blindness. The warning reflects increased scrutiny of GLP-1 drugs amid growing usage. For investors and markets, the FDA’s safety warning may affect companies involved in manufacturing and selling GLP-1 drugs. Increased regulatory attention could impact sales or prescribing patterns of these treatments. Investors should monitor how these developments influence future drug approvals, sales, and potential liability costs for companies marketing GLP-1 medications.
Read More: FDA Issues New Safety Warning on GLP-1 Drugs Like Ozempic and Wegovy
Novo Nordisk (NVO) Raises Annual Outlook on $11.9B Q3 Sales Beat
Novo Nordisk (NVO) reported third-quarter sales of 79.2 billion Danish kroner ($11.9 billion), surpassing FactSet estimates of 73.6 billion kroner. Sales grew 4% year-on-year at constant exchange rates. Adjusted operating profit came in at 31.7 billion kroner, ahead of the expected 28.6 billion kroner. The company upgraded its full-year outlook, now expecting adjusted revenue and operating profit growth between negative 2% and 2% on a constant currency basis. This is more optimistic than its earlier range of negative 6% to flat, which it revised upward in August. Strong sales of its Wegovy weight-loss pill at 5.4 billion kroner exceeded analyst expectations of about 4.5 billion kroner. Additional sales from injectable Wegovy and diabetes drug Ozempic also beat estimates, at 20.4 billion kroner and 29.7 billion kroner respectively. Novo is competing closely with Eli Lilly in the GLP-1 weight-loss drug market, where investor focus remains on next-generation treatments addressing obesity-linked diseases. The company also announced planned CFO Karsten Munk Knudsen’s departure at the end of 2026, with Luigi La Corte from Galderma named as his successor. Investors will watch how the improved sales momentum and outlook revisions might affect annual revenue and profit growth forecasts.
Read More: Novo Nordisk (NVO) Raises Annual Outlook on $11.9B Q3 Sales Beat
Weight-loss Medications: 2M Users Shift Grocery Spending Trends
Over two million people in the UK are now using weight-loss medications such as Wegovy and Mounjaro. Households with at least one GLP-1 user spent an average of £418 less on groceries in the year after starting medication, totaling a national decrease of £780 million. Research from Cornell University shows that US households with one drug user spent 5% less on groceries within six months, rising to 8% for higher-income families. This trend reshapes consumer spending habits, emphasizing healthier food choices while also increasing purchases of items like mouthwash and hair dye. For investors, this information highlights the potential shifts in the retail landscape and spending behavior due to health trends.
Read More: Weight-loss Medications: 2M Users Shift Grocery Spending Trends
Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Read More: Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand
Novo Nordisk (NVO) reported first-quarter revenue of 96.82 billion kroner, a 24% increase year-over-year, largely driven by sales of its Wegovy weight loss pill, which generated 2.26 billion kroner ($353.6 million) from 1.3 million prescriptions. The drugmaker has raised its full-year guidance, now projecting adjusted sales and operating profit to decline between 4% and 12% in constant-currency terms, improving from prior estimates. The CEO noted that Wegovy captures 65% of new U.S. prescriptions in its category. Despite prior challenges, the earnings report indicates a recovery and better growth prospects ahead.
Read More: Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand
Novo Nordisk (NVO) lifts 2026 outlook; shares surge as Wegovy drives growth
Novo Nordisk (NVO) has raised its 2026 revenue outlook substantially, attributing this increase primarily to the strong performance of its weight-loss drug, Wegovy. The company reported a 20% year-on-year increase in sales for the most recent quarter, reaching DKK 54 billion. Following this announcement, NVO shares experienced a notable surge in trading volumes, reflecting increased investor confidence. This revision implies positive implications for future earnings and market position, particularly in the growing obesity management sector.
Read More: Novo Nordisk (NVO) lifts 2026 outlook; shares surge as Wegovy drives growth
Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data
Novo Nordisk (NVO) raised its full-year 2026 profit guidance following better-than-expected sales of its Wegovy weight-loss pill, which reached 2.26 billion kroner in Q1, above estimates of 1.16 billion kroner. The company's shares increased by 6.3% in morning trading, following prior gains over 8%. Adjusted sales and profits are expected to decline between 4% and 12% on a currency-adjusted basis, improving from prior projections. First-quarter sales were reported at 96.8 billion kroner ($15.2 billion), with operating profit surging 65% to 59.6 billion kroner.
Read More: Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More: Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions